Phase III data backs Satraplatin for prostate cancer

GPC Biotech has released Phase III data on its prostate cancer therapy Satraplatin demonstrating that it significantly reduced the threat of disease progression. After six months 30 percent of the volunteers taking satraplatin in combination with prednisone had not progressed compared to 17 percent of the patients in the control group taking prednisone with a placebo. After a year 16 percent of Satraplatin patients hadn't progressed compared to seven percent of the control group. The data was released at a symposium in Orlando.

- see the release on the drug
- read the AFX report on the trial data

ALSO: Antisoma, meanwhile, announced that a mid-stage trial of the prostate cancer therapy AS1404 showed promising results and added that the company is in talks to license the therapy. Report

Related Articles:
GPC posts positive satraplatin data. Report
Shares surge as satraplatin succeeds in Phase III. Report
Pharmion signs $270M licensing deal for GPC's satraplatin. Report